Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the ...

Please provide your email address to receive an email when new articles are posted on . Retinal implants have a history of challenges, and questions remain about their utility. A bioengineered RPE ...

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...

Nanoscope Therapeutics has received Pioneering Regenerative Medical Product (Sakigake) and Orphan Drug designations for ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

—Among patients diagnosed with intermediate-stage age-related macular degeneration, a fair number of eyes in a new analysis showed evidence of geographic atrophy (GA), a leading cause of blindness. It ...